Remicade Ulcerative Colitis Indication Expands To Maintenance Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Remicade becomes the only biologic indicated for inducing and maintaining clinical remission of ulcerative colitis and Crohn’s disease, according to Centocor.
You may also be interested in...
Remicade Psoriasis Approval Marks Debut Of Centocor Dermatology Sales Force
J&J subsidiary also anticipates eventually using the sales force for another psoriasis product it has in its pipeline.
Centocor’s Remicade Approved For Ulcerative Colitis
Remicade becomes the first biologic approved for ulcerative colitis following a priority review, J&J subsidiary Centocor says.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.